Active BE 0783.494.239Private limited company

YNIOS Pharma

Chemin de l'Yerne(VER) 6C ·4537 Verlaine, Belgium· 4 yrs active

Sector: NACE 20420 (20420)

Conclusion Checked

The computed 12-month bankruptcy probability of YNIOS Pharma is 0.7% (low). The 2024 annual accounts show equity of €702k and a net result of €342k. Equity is growing by ~417.3% per year across the filed fiscal years. The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 3 annual accounts.

Key figures

Equity	€702k
Net result	€342k
Active	4 yrs
Publications	6

Snowflake analysis 5 axes · computed by Checked

85 / 100

Exceptional profile — strong across almost every axis.

Health 76

Profitability 100

Solvency 78

Growth 78

Stability 94

Bankruptcy probability (12 mo) Checked model v1 · free

0.7% Low

0%0,5%1,5%4%10%≥25%

Young company +Lower-failure-rate sector −Annual accounts: healthy financial profile −

Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?

Risk Assessment rule-based

0 / 100

Low risk

Trust signals 3 signals

More than 3 years active

Founded in 2022 — past the statistically most fragile first 3 years.

No legal incidents

No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.

Administratively compliant

No FOD Economie strikeouts (UBO, accounts, address, activity).

Administrative Flags 0 events

No administrative flags

Health barometer FY 2024 · computed

76 / 100 Excellent

050100

Unlock the full score breakdown, per-year score history and the indicative credit limit from Starter.

See plans →

Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative — not credit advice.

Financial overview3 NBB filings

Annual accounts filed on 01-08-2025 with the NBB · fiscal year 2024 · micro

Operating resultNet result

Trajectory (indicative)

Projection over 3 fiscal years from the filed annual accounts — not a forecast, the extended trend.

growing Equity: growth of ~417.3%/year over 3 fiscal years — indicative, assuming unchanged policy.

Solid line = filed figures · dashed = extended trend · area = indicative range.

How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil–Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

EBITDA

€392k

— 22–24

Net profit

€342k

— 22–24

Cash flow

€392k

— 22–24

Total assets

€970k

+343.7% 22–24

Equity

€702k

+829.9% 22–24

Working capital

€-1k

— 22–24

Debt

€268k

+87.1% 22–24

Debt ≤ 1y

€268k

+521.2% 22–24

Debt > 1y

€100k

— 22–24

Current ratio

0.99

-15.7% 22–24

Quick ratio

0.99

-15.7% 22–24

Solvency

72.4%

+109.6% 22–24

Debt / equity

0.38

-79.9% 22–24

ROE

48.7%

— 22–24

ROA

35.3%

— 22–24

Interest coverage

326.29

— 22–24

Figures by fiscal year

Highlight YoY changes (±10%)

Fiscal year	2024
Revenue	—
EBITDA	€392k
Net profit	€342k
Cash flow	€392k
Staff costs	—
Income taxes	—
Dividends	—
Total assets	€970k
Equity	€702k
Debt	€268k
of which ≤ 1y	€268k
of which > 1y	—
Working capital	€-1k
Employees (FTE)	—

Ratios (computed)

	2024
Current ratio	0.99
Quick ratio	0.99
Working capital ratio	-0.1%
Solvency	72.4%
Debt / equity	0.38
Long-term debt ratio	—
Interest coverage	326.29
Gross margin	—
Net margin	—
ROA	35.3%
ROE	48.7%
EBITDA margin	—
Days sales outstanding	—
Days payable outstanding	—
Inventory turnover	—
Days inventory (DSI)	—

Balance-sheet composition 2024

Assets

Fixed assets €704k · 72.5% Current assets €266k · 27.5%

Equity & liabilities

Equity €702k · 72.4% Debt €268k · 27.6%

Full annual accounts

Filed balance sheet and income statement, exactly as deposited with the NBB.

Line item	Code	2024
Balance sheet — Assets
TOTAL ASSETS	20/58	€970k
Fixed assets	21/28	€704k
Intangible fixed assets	21	€704k
Current assets	29/58	€266k
Amounts receivable within one year	40/41	€9k
Cash & bank	54/58	€257k
Balance sheet — Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€970k
Equity	10/15	€702k
Contributions / capital	10/11	€692k
Accumulated profits (losses)	14	€11k
Amounts payable	17/49	€268k
Amounts payable within one year	42/48	€268k
Trade debts payable within one year	44	€7k
Income statement
Gross operating margin	9900	€393k
Operating result	9901	€343k
Financial income	75	€236
Financial charges	65	€1k
Result before taxes	9903	€342k
Net result for the period	9904	€342k
Result to be appropriated	9905	€342k

You're seeing the latest fiscal year only. Unlock 2 prior years (figures + ratios) with a paid plan. See plans →

Ratios computed by Checked.

Legal Structure

NACE primary	20420
Legal form	Private limited company(610)
Incorporation	16-03-2022
Status	Active
Postal code	4537

Updates 9 events

A single timeline of everything that happened to this company — publications, insolvency and lifecycle events, administrative changes and filed annual accounts.

2025

01-08-2025

NBB filing Annual accounts filed

fiscal year 2024 · micro

2024

06-12-2024

State Gazette act Capital & shares

David REMY

06-12-2024

State Gazette act Statutes amendment

David REMY

02-07-2024

NBB filing Annual accounts filed

fiscal year 2023 · micro

10-06-2024

State Gazette act Miscellaneous

Conversion legal form · David REMY

10-06-2024

State Gazette act Capital & shares

David REMY

2023

13-07-2023

NBB filing Annual accounts filed

fiscal year 2022 · micro

25-01-2023

State Gazette act Capital & shares

David REMY

2022

28-09-2022

State Gazette act Capital & shares

David REMY

Belgisch Staatsblad — acts 6 acts

Capital history · 4

06-12-2024

Capital change

10-06-2024

Capital change

25-01-2023

Capital change

28-09-2022

Capital change

All acts · 6 updated 1 year ago

2024

06-12-2024 Restructuring of share classes Capital & shares·David REMY

Notary: David REMY · Fernelmont

Original publication ↗

Technical details

{
  "events": [
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "subscribers": [
        {
          "kbo": "0538.839.354",
          "rrn": null,
          "kind": "org",
          "name": "SPREDS FINANCE",
          "share_class": "B1",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 74500,
          "contribution_amount_eur": 74500.0
        }
      ],
      "share_emission": {
        "agio_eur": 0.0,
        "share_form": "no_nominal_value",
        "share_class": "B1",
        "n_new_shares": 74500,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 1.0
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_conversion",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "Pascal VAN HOVE",
          "share_class": null,
          "liberation_pct": null,
          "contribution_kind": null,
          "n_shares_subscribed": null,
          "contribution_amount_eur": null
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "David REMY",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Fernelmont",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-12-06",
    "filing_date": "2024-12-03",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_g\u00E9n\u00E9rale_extraordinaire",
    "act_date": "2024-08-08",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0783.494.239",
    "name_full": "YNIOS Pharma",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [],
  "shareholders_after": [
    {
      "kbo": "0538.839.354",
      "pct": null,
      "kind": "org",
      "name": "SPREDS FINANCE",
      "role": "aandeelhouder",
      "n_shares": 74500,
      "share_class": "B1"
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "Pascal VAN HOVE",
      "role": "aandeelhouder",
      "n_shares": 87400,
      "share_class": "B2"
    }
  ],
  "share_classes_after": [
    {
      "n_shares": 5370000,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 187100,
      "class_name": "B1",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 300000,
      "class_name": "B2",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 2700,
      "class_name": "B3",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 200000,
      "class_name": "B4",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    }
  ]
}

06-12-2024 Articles of association amended — translation of the articles, coordination of the articles and amendment of specific articles Statutes amendment·David REMY

Notary: David REMY · Fernelmont

Original publication ↗

Technical details

{
  "notary": {
    "name": "David REMY",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Fernelmont",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-12-06",
    "filing_date": "2024-12-03",
    "act_kind_objet": "STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), CAPITAL, ACTIONS, DIVERS"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2024-08-08",
    "unanimous": null
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "targeted_amendment"
    ],
    "scope": "full_restatement",
    "trigger": "wvv_adaptation",
    "language_after": "fr",
    "language_before": "fr"
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0783.494.239",
    "name_full_after": "YNIOS Pharma",
    "legal_form_after": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
    "name_full_before": "YNIOS Pharma",
    "current_zetel_raw": "Chemin de l\u2019Yerne, 6C 4537 Verlaine",
    "legal_form_before": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "special_mandates": [
    {
      "holder_kbo": null,
      "holder_name": "David REMY",
      "scope_categories": [
        "publication"
      ],
      "with_substitution": true
    }
  ],
  "articles_modified": [
    {
      "summary": "Remplace le texte de l\u0027article 5 des statuts par un nouveau texte d\u00E9taillant l\u0027\u00E9mission et la r\u00E9partition des actions en cinq cat\u00E9gories.",
      "new_text": "Article 5. Apports\nEn r\u00E9mun\u00E9ration des apports, 6.059.800 actions ont \u00E9t\u00E9 \u00E9mises, r\u00E9parties en 5 cat\u00E9gories :\n \u2022 5.370.000 actions de cat\u00E9gorie A (FONDATEURS) ;\n \u2022 187.100 actions de cat\u00E9gorie B1 (SPREDS FINANCE Tax Shelter) ;\n \u2022 300.000 actions de cat\u00E9gorie B2 (PRIVES Tax Shelter) ;\n \u2022 2.700 actions de cat\u00E9gorie B3 (SPREDS FINANCE Normal) ;\n \u2022 200.000 actions de cat\u00E9gorie B4 (PRIVES Normal).\nChaq",
      "change_kind": "replaced",
      "article_title": "Apports",
      "article_number": "5"
    }
  ],
  "governance_change": null,
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "David REMY",
    "org_rep_person_name": null
  },
  "co_filed_documents": [],
  "shareholder_rights": {
    "quorum_rules_changed": false,
    "liquidation_preference_text": null,
    "voorkeurrecht_rules_changed": true,
    "aandelenoverdracht_restrictions_changed": false
  },
  "voorwerp_change_summary": null,
  "capital_structure_change": {
    "operations": [
      "share_class_creation"
    ],
    "split_ratio": null,
    "shares_after": null,
    "shares_before": null,
    "capital_after_eur": null,
    "capital_before_eur": null,
    "share_classes_after": [
      {
        "count": 74500,
        "label": "B1",
        "rights_summary": "Souscription nouvelle, r\u00E9gime Tax Shelter",
        "voting_per_share": null
      },
      {
        "count": 300000,
        "label": "B2",
        "rights_summary": "PRIVES Tax Shelter",
        "voting_per_share": null
      },
      {
        "count": 2700,
        "label": "B3",
        "rights_summary": "SPREDS FINANCE Normal",
        "voting_per_share": null
      },
      {
        "count": 200000,
        "label": "B4",
        "rights_summary": "PRIVES Normal",
        "voting_per_share": null
      }
    ]
  },
  "coordinated_text_lineage": null
}

10-06-2024 Publication in the Belgian Official Gazette — Miscellaneous Miscellaneous·David REMY

Summary: Conversion legal formNotary: David REMY · Fernelmont

Original publication ↗

Technical details

{
  "stage": null,
  "notary": {
    "name": "David REMY",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Fernelmont",
    "is_associated": false
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2024-06-10",
    "filing_date": "2024-06-06",
    "act_kind_objet": "STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), CAPITAL, ACTIONS, DIVERS"
  },
  "decision": {
    "body": "algemene_vergadering",
    "act_date": "2024-03-19",
    "unanimous": null
  },
  "conversion": {
    "effective_date": null,
    "jurisdiction_to": null,
    "legal_form_after": null,
    "jurisdiction_from": null,
    "legal_form_before": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "detected_kind": "conversion_legal_form",
  "report_waiver": {
    "summary": "The shareholders waived their preferential subscription right under article 7 of the statutes.",
    "articles": [
      "7"
    ]
  },
  "restructuring": {
    "parties": [
      {
        "kbo": "0783.494.239",
        "name": "YNIOS Pharma",
        "role": "contributor",
        "address": "Chemin de l\u2019Yerne, 6C, 4537 Verlaine",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": null
      },
      {
        "kbo": "0538.839.354",
        "name": "SPREDS FINANCE",
        "role": "contributor",
        "address": null,
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 anonyme",
        "is_new_company": false,
        "jurisdiction_country": null
      },
      {
        "kbo": null,
        "name": "Pascal VAN HOOVE",
        "role": "contributor",
        "address": null,
        "is_foreign": false,
        "legal_form": null,
        "is_new_company": false,
        "jurisdiction_country": null
      },
      {
        "kbo": null,
        "name": "Ilse DE GROOTE",
        "role": "contributor",
        "address": null,
        "is_foreign": false,
        "legal_form": null,
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "7"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 5985300,
    "real_estate_included": false,
    "patrimony_description": null,
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0783.494.239",
    "name_full": "YNIOS Pharma",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "David REMY",
    "org_rep_person_name": null
  },
  "summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de YNIOS Pharma a pris des r\u00E9solutions pour augmenter le nombre d\u0027actions, cr\u00E9er de nouvelles cat\u00E9gories d\u0027actions et souscrire \u00E0 ces nouvelles actions aupr\u00E8s de partenaires certifi\u00E9s et d\u0027investisseurs priv\u00E9s. Parall\u00E8lement, les statuts ont \u00E9t\u00E9 modifi\u00E9s pour refl\u00E9ter ces apports.",
  "co_filed_documents": [],
  "detected_real_type": "other",
  "referenced_correction": {
    "prior_pub_date": "2022-03-18",
    "what_corrected": null,
    "prior_pub_number": "22318105"
  },
  "should_reroute_to_category": null
}

10-06-2024 Restructuring of share classes Capital & shares·David REMY

Notary: David REMY · Fernelmont

Original publication ↗

Technical details

{
  "events": [
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "subscribers": [
        {
          "kbo": "0538.839.354",
          "rrn": null,
          "kind": "org",
          "name": "SPREDS FINANCE",
          "share_class": "B1",
          "liberation_pct": 100.0,
          "contribution_kind": null,
          "n_shares_subscribed": 7600,
          "contribution_amount_eur": null
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": "B1",
        "n_new_shares": 7600,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "subscribers": [
        {
          "kbo": "0538.839.354",
          "rrn": null,
          "kind": "org",
          "name": "SPREDS FINANCE",
          "share_class": "B2",
          "liberation_pct": 100.0,
          "contribution_kind": null,
          "n_shares_subscribed": 87400,
          "contribution_amount_eur": null
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": "B2",
        "n_new_shares": 87400,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": 87400,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "subscribers": [
        {
          "kbo": "0538.839.354",
          "rrn": null,
          "kind": "org",
          "name": "SPREDS FINANCE",
          "share_class": "B3",
          "liberation_pct": 100.0,
          "contribution_kind": null,
          "n_shares_subscribed": 2700,
          "contribution_amount_eur": null
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": "B3",
        "n_new_shares": 2700,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": 2700,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "Pascal VAN HOOVE",
          "share_class": "B4",
          "liberation_pct": 100.0,
          "contribution_kind": null,
          "n_shares_subscribed": 87600,
          "contribution_amount_eur": null
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "Ilse DE GROOTE",
          "share_class": "B4",
          "liberation_pct": 100.0,
          "contribution_kind": null,
          "n_shares_subscribed": 25000,
          "contribution_amount_eur": null
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": "B4",
        "n_new_shares": 112600,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": 112600,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "David REMY",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Fernelmont",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-06-10",
    "filing_date": "2024-06-06",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2024-03-19",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0783.494.239",
    "name_full": "YNIOS Pharma",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [],
  "shareholders_after": [
    {
      "kbo": "0538.839.354",
      "pct": null,
      "kind": "org",
      "name": "SPREDS FINANCE",
      "role": null,
      "n_shares": 5370000,
      "share_class": "A"
    },
    {
      "kbo": "0538.839.354",
      "pct": null,
      "kind": "org",
      "name": "SPREDS FINANCE",
      "role": null,
      "n_shares": 112600,
      "share_class": "B1"
    },
    {
      "kbo": "0538.839.354",
      "pct": null,
      "kind": "org",
      "name": "SPREDS FINANCE",
      "role": null,
      "n_shares": 387400,
      "share_class": "B2"
    },
    {
      "kbo": "0538.839.354",
      "pct": null,
      "kind": "org",
      "name": "SPREDS FINANCE",
      "role": null,
      "n_shares": 2700,
      "share_class": "B3"
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "Pascal VAN HOOVE",
      "role": null,
      "n_shares": 87600,
      "share_class": "B4"
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "Ilse DE GROOTE",
      "role": null,
      "n_shares": 25000,
      "share_class": "B4"
    }
  ],
  "share_classes_after": [
    {
      "n_shares": 5370000,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 112600,
      "class_name": "B1",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 387400,
      "class_name": "B2",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 2700,
      "class_name": "B3",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 112600,
      "class_name": "B4",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    }
  ]
}

2023

25-01-2023 Restructuring of share classes Capital & shares·David REMY

Notary: David REMY · Fernelmont

Original publication ↗

Technical details

{
  "events": [
    {
      "kind": "share_class_conversion",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": 5575000,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": 200000.0,
      "before_eur": null,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "PASCAL VAN HOVE",
          "share_class": "B2",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 100000,
          "contribution_amount_eur": 100000.0
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "Madame DE GROOTE Ilse Leonce",
          "share_class": "B2",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 100000,
          "contribution_amount_eur": 100000.0
        }
      ],
      "share_emission": {
        "agio_eur": 0.0,
        "share_form": null,
        "share_class": "B2",
        "n_new_shares": 200000,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 1.0
      },
      "decrease_purpose": null,
      "contribution_type": "geld",
      "paid_up_delta_eur": 200000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "statutory_reserve_release",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
    },
    {
      "kind": "other",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "David REMY",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Fernelmont",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2023-01-25",
    "filing_date": "2023-01-23",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e g\u00E9n\u00E9rale extraordinaire",
    "act_date": "2023-01-17",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0783.494.239",
    "name_full": "YNIOS Pharma",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 5370000,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 105000,
      "class_name": "B1",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 300000,
      "class_name": "B2",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    }
  ]
}

2022

28-09-2022 Restructuring of share classes Capital & shares·David REMY

Notary: David REMY · Fernelmont

Original publication ↗

Technical details

{
  "events": [
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_transfer",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "org",
          "name": "SPREDS FINANCE",
          "share_class": "B1",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 105000,
          "contribution_amount_eur": 105000.0
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "VAN HOVE Pascal Urbain",
          "share_class": "B2",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 100000,
          "contribution_amount_eur": 100000.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "statutory_reserve_release",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "convert_to_distributable"
    }
  ],
  "notary": {
    "name": "David REMY",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Fernelmont",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2022-09-28",
    "filing_date": "2022-09-26",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2022-09-06",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0783.494.239",
    "name_full": "YNIOS Pharma",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Ghislaine",
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [],
  "shareholders_after": [
    {
      "kbo": "0783.494.239",
      "pct": null,
      "kind": "org",
      "name": "YNIOS Pharma",
      "role": "aandeelhouder",
      "n_shares": 5370000,
      "share_class": "A"
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "org",
      "name": "SPREDS FINANCE",
      "role": "aandeelhouder",
      "n_shares": 105000,
      "share_class": "B1"
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "VAN HOVE Pascal Urbain",
      "role": "aandeelhouder",
      "n_shares": 100000,
      "share_class": "B2"
    }
  ],
  "share_classes_after": [
    {
      "n_shares": 5370000,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 105000,
      "class_name": "B1",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 100000,
      "class_name": "B2",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    }
  ]
}

Credit advice verdict per customer and amount

AI due-diligence brief Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon

AI-generated from Checked data; indicative, not legal or investment advice.

Company registry (CBE) Crossroads Bank

Activities

Vervaardiging van parfums en toiletartikelen20420Vervaardiging van parfums en toiletartikelen20420Detailhandel in cosmetica en toiletartikelen in gespecialiseerde winkels47750Detailhandel in cosmetica en toiletartikelen47750Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110

Primary activity highlighted.

Names & trade names

Legal nameFR

YNIOS Pharma

Registered office

Chemin de l'Yerne(VER) 6C

4537 Verlaine, Belgium

Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.

Similar companies Same NACE

Yui Skin BE 0794.837.893 · Leuven

ALOÏSE BE 0784.424.251 · Antwerpen

ALLOPHARM.BE BE 0474.254.378 · Waremme

BESTIALE MAKEUP BE 0804.713.780 · Ans

BIOCARE BE 0669.941.683 · Juprelle